- Home
- PRLD vs NXN Comparison
PRLD vs NXN Comparison
Compare PRLD & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- NXN
- Stock Information
- Founded
- PRLD 2016
- NXN 1992
- Country
- PRLD United States
- NXN United States
- Employees
- PRLD N/A
- NXN N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- NXN Trusts Except Educational Religious and Charitable
- Sector
- PRLD Health Care
- NXN Finance
- Exchange
- PRLD Nasdaq
- NXN Nasdaq
- Market Cap
- PRLD 50.1M
- NXN 45.3M
- IPO Year
- PRLD 2020
- NXN N/A
- Fundamental
- Price
- PRLD $0.89
- NXN $11.53
- Analyst Decision
- PRLD Strong Buy
- NXN
- Analyst Count
- PRLD 2
- NXN 0
- Target Price
- PRLD $4.50
- NXN N/A
- AVG Volume (30 Days)
- PRLD 137.5K
- NXN 9.7K
- Earning Date
- PRLD 05-06-2025
- NXN 01-01-0001
- Dividend Yield
- PRLD N/A
- NXN 4.23%
- EPS Growth
- PRLD N/A
- NXN N/A
- EPS
- PRLD N/A
- NXN 0.24
- Revenue
- PRLD $7,000,000.00
- NXN N/A
- Revenue This Year
- PRLD N/A
- NXN N/A
- Revenue Next Year
- PRLD N/A
- NXN N/A
- P/E Ratio
- PRLD N/A
- NXN $48.42
- Revenue Growth
- PRLD N/A
- NXN N/A
- 52 Week Low
- PRLD $0.61
- NXN $10.64
- 52 Week High
- PRLD $6.80
- NXN $12.45
- Technical
- Relative Strength Index (RSI)
- PRLD 51.42
- NXN 48.77
- Support Level
- PRLD $0.77
- NXN $11.38
- Resistance Level
- PRLD $1.00
- NXN $11.69
- Average True Range (ATR)
- PRLD 0.11
- NXN 0.15
- MACD
- PRLD -0.01
- NXN -0.01
- Stochastic Oscillator
- PRLD 37.18
- NXN 20.27
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.